

BLAU FARMACÊUTICA S.A.

Publicly Held Company
NIRE 35.300.416.406
CVM Code No. 2462-7

NOTICE TO SHAREHOLDERS**Scheduled date for the 2026 Annual Shareholders Meeting**

BLAU FARMACÊUTICA S.A. (Ticker: BLAU3; “Blau” or “Company”) in compliance with the CVM Instruction No. 81/2022, informs its shareholders and the market in general that the scheduled date for its Annual Shareholders’ Meeting is April 22, 2026. The company clarifies that it will make available the other information related to the event in due course, in accordance with the applicable legislation.

Cotia, January 14, 2026

Douglas Leandro Rodrigues
Chief Financial and Investor Relations Officer

About Blau Farmacêutica:

Blau is a leading multinational pharmaceutical company in the hospital segment and a pioneer in biotechnology in Brazil, with a portfolio of proprietary brands of highly complex medicines focused on relevant segments in the industry, such as immunology, hematology, oncology, nephrology, infectious diseases, and several other therapeutic classes. Blau has an international presence, operating in Brazil and seven other Latin American countries (Argentina, Colombia, Chile, Ecuador, Mexico, Peru, and Uruguay), in addition to a plasma collection operation in the United States. It has a modern pharmaceutical industrial complex in Brazil, consisting of five industrial plants with state-of-the-art technology, dedicated to serving the local market and exports.